BCL2 and metabolic dysfunction-associated steatotic liver disease: Previous studies establishing the i-motif within the BCL2 promoter as a transcriptional activator [46,47] support the premise that stabilization of the BCL2 i-motif in NAFLD and NASH is an effective approach to increase BCL2 levels and prevent hepatocyte apoptosis.